CSB-001 is under clinical development by Claris Biotherapeutics and currently in Phase I for Limbal Stem Cell Deficiency (LSCD). According to GlobalData, Phase I drugs for Limbal Stem Cell Deficiency (LSCD) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CSB-001 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CSB-001 overview
CSB-001 is a under development for the treatment of stage 2 and 3 neurotrophic keratitis, limbal stem cell deficiency and corneal scars. It is administered through ophthalmic route as drops. The solution constitutes a human recombinant dHGF (5-amino acid deleted hepatocyte growth factor).
Claris Biotherapeutics overview
Claris Biotherapeutics is developing ocular biologic solution for the treatment of neurotrophic keratitis. The company is headquartered in Jersey City, New Jersey, the US.
For a complete picture of CSB-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.